Abstract

Sexuality is a significant quality-of-life concern for many cancer patients. Patients may be disadvantaged if they are not informed and not offered sexual health care. We sought to reveal oncologists’ current practice and opinions concerning sexual counselling. The aim of this study was to explore the knowledge, attitude and practice patterns of Dutch medical oncologists regarding treatment-related sexual dysfunction. Questionnaires were sent to 433 members of the Dutch Society of Medical Oncology. The majority (81.5%) of the 120 responding medical oncologists (response rate 30.6%) stated they discussed sexual function with fewer than half of their patients. At the same time, 75.8% of the participating oncologists agreed that addressing sexual function is their responsibility. Sexual function was discussed more often with younger patients and patients with a curative treatment intent. Barriers for avoiding discussing sexual function were lack of time (56.1%), training (49.5%) and advanced age of the patient (50.4%). More than half (64.6%) stated they had little knowledge about the subject and the majority (72.9%) wanted to acquire additional training in sexual function counselling. Medical oncologists accept that sexual function counselling falls within their profession, yet they admit to not counselling patients routinely concerning sexual function. Only in a minority of cases do medical oncologists inform their patients about sexual side effects of treatment. Whether they counsel patients is related to how they view patient’s prognosis, patient’s age, and self-reported knowledge. Findings indicate there is a role for developing education and practical training.

Keywords

Sexual health care . Oncology . Quality-of-life . Communication . Sexual dysfunction

Introduction

It is widely known that sexual dysfunction is a common side effect of oncological disease. All cancer therapies, including chemo-, hormonal- and immunotherapy, radiation and surgery can impair the sexual function. The prevalence of sexual side effects following therapy varies, depending on cancer and therapy type, but may even rise to 100% after treatment of genital cancers [1–5]. Cancer patients often face sexual symptoms from the start of treatment and these are likely to continue or even increase in the long term [6]. The consequences of cancer treatment can influence all aspects of sexuality, including desire, satisfaction and functioning. Sexuality is considered an extremely important quality-of-life concern by cancer survivors [7–9]. Despite reporting concerns regarding their sexual function, patients are frequently not informed about how treatment may affect their sexual function [1, 10, 11].

Given the high prevalence of sexual dysfunction and the complexity of the problems, an integrative approach to potential sexual problems is needed. Literature reveals a mismatch in expectations between the patient and healthcare providers regarding communication about sexuality [12–14]. Patients reported unmet needs regarding discussing sexuality with their health care providers. While some patients wish to discuss this topic, they feel health care providers do not provide an opportunity to talk about sexual function or even ignore their sexual needs [5, 11, 12, 15–17]. On the other hand, not all healthcare professionals consider it their task to discuss the subject [18].
Moreover, they face several other barriers, such as uncomfortable feelings, insufficient knowledge, lack of training, lack of time and over involvement in aspects of patients’ personal lives. Oncology care providers do, however, consider sexual function to be an important topic [18–21]. During cancer treatment, patients are treated by different professionals within a multidisciplinary team. It is not always clear which member of the team is responsible for addressing sexual function. Studies among different Dutch oncology care providers revealed that members of the oncology team, like radiation oncologists, oncology nurses and oncology surgeons, see some role for themselves in sexual function counselling, but all point to the medical oncologist to bring up the subject [19–21].

Consequently, it is important to identify how medical oncologists report their own role in sexual counselling. An understanding of how medical oncologists acquire knowledge about sexual function counselling, how they apply sexual function counselling in practice, and which barriers they may encounter when bringing up the subject is needed to optimise management around sexual care for oncology patients. The aim of this study is to explore the attitude, practice patterns and education needs of medical oncologists regarding sexual function counselling.

Instrument Design and Development

The questionnaire consisted of 38 questions (Appendix 1). It contained questions on demographics, frequency of discussing sexual function, the patient’s view about the responsibility for discussing sexual function, barriers faced when discussing sexual function, self-reported knowledge about sexual function after cancer treatment and the need for additional training. The questionnaire was developed by the authors based on several items found in relevant literature and on previously conducted sexuality questionnaire studies among health care professionals. The latter was derived from our research group and concerned questions about practice patterns, knowledge, barriers and responsibility regarding treatment-related sexual function [19–21]. The content of the questionnaire was pilot-tested by four oncologists from the area of Leiden, the Netherlands. A small pilot panel was chosen because of the limited number of oncologists in the Netherlands; the members of the pilot panel were not invited for the survey. The pilot panel reviewed the questionnaire with regard to relevance, integrity, structure, layout and spelling.

Methods

Study Design

A questionnaire was used to collect data in a cross-sectional survey. The questionnaire was sent to 433 members of the NVMO (Dutch Society of Medical Oncology). The total number was 440, but 7 members living and practising oncology abroad were excluded (most of them from the Netherlands Antilles). Members of the NVMO include both medical oncologists and oncology differentiating residents. Our sampling strategy aimed to represent area of expertise, employment setting, level of education, years of oncology experience, type of hospital, age and gender.

Survey Administration

The questionnaires and reminders were sent in 2014. Non-responders received a reminder twice. The questionnaires were sent by post and included a stamped, addressed envelope. Reason for using a postal survey was to obtain the highest possible response rate. In studies with participants between 30 and 60 years old or older, the highest response rate was seen in postal surveys [22–24]. We expected the average age of our respondents to be older than 30 years. Furthermore, we wanted to prevent younger, male, avid Internet users and those with greater technological interest to be over-represented in the survey [22, 25].

Ethical Consideration

The study was formally approved by the scientific committee of the Department of Urology of the LUMC. In the Netherlands, research that does not involve patients or interventions is not subject to permission from ethical boards. In previous research using similar types of questionnaires, the Medical Ethics Committee was consulted by our research group. As the study did not concern information recorded by the investigator in such a manner that subjects could be identified, and as it did not compromise the study participants’ integrity, the Committee declared that no formal ethical approval was needed.
Results

Participants

The survey was distributed among 433 medical oncologists; 209 of them responded (initial response rate 48.3%). Of these 209 responders, nine were returned to sender, 26 oncologists reported they had retired and 6 were not medical oncologists. A notification of refusal was received from 48, 39.3% (n = 35) of whom refused due to lack of time. Of 392 eligible participants, 120 completed questionnaires were returned and included for analysis, resulting in a final response rate of 30.6%.

The mean age of the respondents was 47 years (range 30–64) and half of them (n = 56 52.5%) were male. The male respondents were significantly older than female respondents (p < 0.001). The majority (n = 72, 61%) reported > 5 years of experience working in the field of oncology. Areas of expertise and clinical settings are presented in Table 1.

Addressing Sexuality in Medical Practice

The medical oncologists participating in this survey estimated that 70.6% (SD 17.21, range 20–100%) of their patients may experience sexual changes as a result of cancer treatment. Most respondents (n = 97, 81.5%) reported discussing sexual function in fewer than 50% of their patients. There was no significant difference in frequency of discussing sexual function between male and female specialists, years of experience or age of the oncologist (resp. p = 0.503, p = 0.471, p = 0.178). Three-quarters (n = 90) of the responding oncologists stated that they discussed sexual function in fewer than half of the cases during the informed consent conversation before the start of treatment. Findings are summarized in Table 2. The main topics being discussed were decreased libido (n = 65, 72.2%), menopausal symptoms (n = 63, 70%), insufficient lubrication (n = 60, 66.7%) and pain during intercourse (n = 48, 53.3%) in women. Erectile dysfunction (n = 74, 82.2%) and decreased libido (n = 73, 81.1%) were frequently discussed with male patients.

Among oncologists who did discuss sexual function, 91.4% (n = 83) reported addressing this subject when treatment had a curative intent. This declined to 62.4% (n = 57) when the treatment had a life-prolonging intent and to 33.3% (n = 30) in cases of palliative treatment. The oncologists discussed sexuality more often with younger patients. Sixty-eight per cent (n = 61) of the respondents discussed sexuality regularly/always with patients between 20 and 35 years of age; this percentage declined to 2.2% (n = 2) in patients older than 75 years. All age groups are represented in Fig. 1.

Table 1  Participant characteristics

| Oncologists (n = 120) |
|----------------------|
| Median age in years (range) | 47 (30–64) |
| Age of male respondents (years) | 50.6 (SD 10) |
| Age of female respondents (years) | 41.9 (SD 8.9) |
| Gender |
| Male | n (%) |
| 56 | 46.7 |
| Female | 63 | 52.5 |
| Unknown | 1 | 0.8 |
| Function |
| Oncologist | 101 | 84.2 |
| Oncology resident | 19 | 15.8 |
| Area of expertisea |
| Breast | 88 | 73.3 |
| Colorectal | 79 | 65.8 |
| Palliative care | 57 | 47.5 |
| Gynaecology | 53 | 44.2 |
| Nephrology and urology | 53 | 44.2 |
| Haematology | 37 | 30.8 |
| Lymphoma | 32 | 26.7 |
| Head and neck | 14 | 11.7 |
| Neuroendocrine | 14 | 11.7 |
| Melanoma | 8 | 6.7 |
| Sarcomas | 8 | 6.7 |
| Lung | 3 | 2.5 |
| Type of practice |
| District general hospital | 47 | (39.2) |
| University hospital | 40 | (33.3) |
| District general teaching hospital | 27 | (22.5) |
| Cancer institute | 3 | (2.5) |
| Both university and district | 2 | (1.7) |
| Unknown | 1 | (0.8) |
| Oncology experience |
| < 1 year | 0 |
| 1–2 years | 19 | (15.8) |
| 3–5 years | 27 | (22.5) |
| 6–10 years | 13 | (10.8) |
| 11–15 years | 19 | (15.8) |
| > 15 years | 40 | (33.3) |
| Unknown | 2 | (1.7) |

*Most respondents reported multiple areas of expertise*

Responsibility and Barriers

Of all oncologists, a large majority of 75.8% (n = 91) stated they felt responsible for discussing sexual function with their patients. A similar percentage (75%, n = 90) indicated they considered the oncology nurse also to be responsible and half of the respondents (n = 61) thought the patient was responsible for initiating the subject. Responsibility allocated to possible
health care providers and the patient or partner is displayed in Table 3. A minority (n = 14, 12.8%) of respondents stated there was an agreement defining responsibility for discussing sexual function within their multidisciplinary team.

According to the medical oncologists, the major barriers for discussing sexual function were ‘lack of time’ (n = 64, 56.1%), ‘advanced age of the patient’ (n = 57, 50.4%), ‘lack of training’ (n = 51, 49.5%) and ‘patient is too ill’ (n = 51, 49.5%). Less-experienced oncologists (≤10 years of practice) stated lack of time as a reason more often than their more experienced colleagues (p = 0.006). Other barriers to avoid having to address sexual function are listed in Table 4.

Knowledge, Education and Training Needs

A small percentage of the respondents (n = 14, 15.4%) stated they had sufficient knowledge to be able to discuss the subject. All other respondents (n = 77, 84.6%) stated having little or no knowledge of the subject. Oncologists with more self-stated knowledge discussed sexual function more often (p = 0.002). According to 85% (n = 102), education about sexual function counselling within their oncological training was insufficient. A majority of 72.9% (n = 86) would like to acquire more training in the counselling of sexual function, regardless of their self-stated knowledge (p = 0.733). No significant differences were found in training needs between areas of expertise.

Discussion

The present study provides insight into the practice patterns of Dutch medical oncologists with regard to discussing sexual function. It reveals the origins of several difficulties in discussing sexual function in current clinical practice. Medical oncologists do see sexual function counselling as part of their duty. Nevertheless, they do not routinely counsel sexual function due to several barriers, such as lack of training. A minority informs their patients about potential sexual side effects of planned cancer treatment. Whether oncologists counsel patients is related to the age of the patient, how they view the patient’s prognosis and to whether they stated they had more knowledge about sexual function.

The results of this study are in line with other self-reported surveys among oncology health care providers about communication regarding sexual concerns. To our knowledge, this is the first study to describe how medical oncologists see their role in sexual counselling, depicting the actual origin of difficulties in discussing sexual issues in current clinical practice.

According to our data, Dutch oncologists rarely bring up sexual side effects during the informed consent conversation before starting a treatment. Informed consent is seen as a crucial component of medical practice and authenticates patients’ autonomy. During informed consent, adverse effects that are common should be discussed [26]. Given the high prevalence and additional burden of sexual dysfunction after cancer treatment, sexual side effects of treatment should be part of
informed consent [1–5, 26]. Lack of knowledge, lack of time and lack of clarity about sexual side effects in current guidelines may result in ambiguity regarding responsibility for discussing sexual side effects [18]. An example of how to enhance communication about sexual side effects during informed consent is the use of an informed consent template, provided by the ASCO, where side effects, including sexual side effects are mentioned [27]. Nevertheless, a form cannot replace direct patient-provider communication but could help the care provider to address the subject.

Since sexual problems can arise during early treatment, but may also arise after treatment and even extend long term, discussing sexual function during the whole cancer care process would seem to be important [6]. However, the current survey revealed that Dutch oncologists do not routinely bring up the subject of sexuality during treatment and follow-up. According to the literature, other members of the multidisciplinary oncological team identified discussing sexual function as a responsibility of the oncologist [19–21]. Members of the multidisciplinary oncological team seem to count on each other to tackle the conversation about sexual health. This highlights the importance of defining responsibilities within the oncology treatment team. According to this survey, only 12.8% of the respondents reported a clearly defined responsibility for addressing sexuality within their team. De Vocht et al. described a Stepped-Skills-model, which could be of help to define responsibilities [18]. In this team-approach-model, there are team members who are ‘spotters’. These spotters, most likely the oncologist, discuss the sexual side effects of treatment, check whether patients need help and refer them where necessary. Other members, most probably the specialized nurses, are called ‘skilled companions’. They have the responsibility to support patients in their sexuality issues. Consequently, these members require training to improve their communication skills and their knowledge. Using such an integrated approach, sexual health may become part of daily clinical practice.

Table 3  Responsibility for addressing sexual health according to the oncologists

| Who is responsible for addressing sexual function? (multiple answers possible) | n (%) |
|---|---|
| Oncologist | 91 (75.8) |
| Oncology nurse | 90 (75) |
| Patient | 61 (50.8) |
| Partner of patient | 28 (23.3) |
| General practitioner | 28 (23.3) |
| Psychologist | 14 (11.7) |
| Social worker | 6 (5) |
| Physiotherapist | 1 (0.8) |

Table 4  List of boundaries for discussing sexual function

| Reasons for avoiding discussion of sexual health | Total respondents* | Agree* (%) | Partly agree/disagree | Disagree* n (%) |
|---|---|---|---|---|
| Lack of time | 114 | 64 (56.1) | 27 (23.7) | 23 (20.2) |
| Advanced age of the patient | 113 | 57 (50.4) | 26 (23) | 30 (26.5) |
| Lack of training | 113 | 51 (45.9) | 35 (31) | 27 (23.9) |
| Patient is too ill | 114 | 51 (44.6) | 35 (30.7) | 28 (24.6) |
| No angle or motive for asking | 114 | 45 (39.5) | 39 (34.2) | 30 (26.3) |
| Lack of knowledge | 114 | 41 (36) | 40 (35.1) | 33 (28.9) |
| Patient does not bring up the subject | 114 | 38 (33.3) | 32 (28.1) | 44 (38.6) |
| Culture/religion | 114 | 27 (23.7) | 34 (29.8) | 53 (45.6) |
| Language/ethnicity | 113 | 27 (23.9) | 28 (24.8) | 58 (51.3) |
| Surviving is more important | 115 | 26 (23.1) | 37 (32.7) | 50 (44.2) |
| I feel uncomfortable | 115 | 26 (22.8) | 37 (32.5) | 51 (44.7) |
| Sexuality is not a matter of life or death | 114 | 25 (21.9) | 37 (32.5) | 52 (45.7) |
| Not relevant for all types of cancer | 114 | 25 (21.9) | 23 (20.2) | 66 (57.9) |
| Presence of a third party | 111 | 24 (21.6) | 26 (23.4) | 61 (54.9) |
| Patient is not ready to discuss sexual health | 102 | 22 (19.7) | 34 (30.4) | 46 (50) |
| Sexuality is a private matter | 131 | 21 (18.6) | 53 (31) | 57 (50.5) |
| Embarrassment | 114 | 20 (17.6) | 32 (28.1) | 62 (52.3) |
| It is someone else’s task | 113 | 17 (15) | 27 (23.9) | 69 (61) |
| No trust in treatment for sexual dysfunction | 112 | 13 (11.6) | 32 (28.6) | 67 (59.8) |
| Concerned about causing the patient discomfort | 114 | 12 (10.5) | 30 (26.3) | 72 (63.1) |
| Sexuality is not a patient’s concern | 114 | 11 (9.7) | 37 (32.5) | 66 (57.9) |
| Age difference between you and patient | 114 | 10 (8.8) | 21 (18.4) | 83 (72.8) |
| Afraid to offend the patient | 114 | 6 (5.3) | 15 (13.2) | 93 (81.5) |
| Patient is the opposite gender | 114 | 4 (3.5) | 16 (14) | 94 (82.4) |
| Patient is the same gender | 112 | 0 (0) | 7 (6.3) | 105 (93.7) |
| Colleagues think it is inappropriate to discuss sexual issues with patients | 113 | 0 (0) | 11 (9.7) | 102 (90.3) |

*Not all respondents answered each question
As already highlighted in the ‘Introduction’ section, a mismatch in expectations regarding the discussion of sexual health between patient and providers does exist. The current study reveals some of the reasons why medical oncologists do not bring up sexuality, which may contribute to this mismatch. Of the respondents, almost 60% stated the ‘advanced age of the patient’ as a barrier to discussing sexual function, suggesting respondents may assume elderly patients are not sexually active. This may be an incorrect assumption. A study on the prevalence of sexual activity among 10,000 European adults showed that sexual desire and activity persist through old age, with 53% of the male respondents and 21% of the female respondents between 70 and 80 years of age being sexually active [28].

Another barrier to discussing sexuality mentioned by almost half of the oncologists involved ‘the patient being too ill’. Also, frequency of bringing up sexual health declined when treatment had a palliative intent compared to a curative intent. A study reviewing sexual healthcare for cancer patients receiving palliative care confirmed a lack of sexual health care in this patient group, although the patients and their partners did feel the need for a conversation about the subject. Bringing up the subject of sexuality by a healthcare professional even improved quality of life and reduced stress of patients and partners [29]. An interdisciplinary approach is required to recognise and manage symptoms in this palliative group.

In accordance with previous investigations, important reasons for the lack of frequency in discussing sexual health were a ‘lack of training’ and a ‘lack of knowledge’ [15, 19–21]. These evidently recurrent barriers among different cancer care providers in different countries indicate that there is a role for education and practical training to improve the situation in practice. A pilot study involving 82 oncology providers showed that a brief (30–34 min) targeted sexual health training significantly enhanced the frequency of discussing sexual issues with cancer patients [30]. In Iceland, a sexual health care educational intervention was implemented over a 2-year time period. Over 200 oncology nurses and physicians participated. The study showed that the perceived level of knowledge in providing sexual health care was higher after the intervention [31]. Furthermore, communication tools, using standard patient questionnaires on sexuality resulted in improved communication between the patient and the health care provider regarding sexual function [32]. However, with the increasing pressure on daily practice of physicians and nurses, and taking another major barrier—lack of time—into consideration, we are urged to look for additional ways of providing sexual health care. Possibilities for educating patient and partner regarding sexual function during and after cancer treatment, like e-health, using websites, videos and apps, have to be further investigated and evaluated.

Some limitations need to be considered. As no validated questionnaires were available, a non-validated questionnaire was administered. The use of a self-reported questionnaire may have led to under- or overestimation. Questionnaire-based studies are always subjected to response and selection bias. A sampling error may have occurred due to the low response rate, although this rate was comparable to that found by other questionnaire studies. There may be a difference between the oncologists who responded and those who did not respond to our questionnaire, possibly creating a bias. The fact that a postal survey was used may have resulted in incomplete responses. Internet questionnaires are known to have a higher degree of completeness since the researcher is able to compensate for errors among respondents who for example accidentally pass over a question [24]. The subdivisions by area of specialization resulted in small numbers of medical oncologists in each group. For this reason, it was not possible to do proper sub-analyses per area. The area of specialisation of the majority of the responding oncologists was breast cancer. The questionnaire may, therefore, have been answered in the context of breast cancer, meaning the patients were slightly younger and were receiving (neo) adjuvant chemotherapy or hormonal therapy, with the accompanying effects on sexual functioning. A larger study among medical oncologists from different countries might be useful in defining differences between areas of specialisation.

The results of this study may improve the awareness of health care professionals in cancer treatment, especially medical oncologists, about the need to define the place of sexual health care in the course of the disease trajectory, to discuss if a specific team member is responsible for initiating the subject and, if necessary, provide additional training.

**Conclusion**

The current study reveals that medical oncologists do not routinely counsel patients concerning sexual function being confronted by several barriers, although they do see this as part of their role. Patients’ prognosis, patients’ age and how knowledgeable the oncologist is about sexual function influence the frequency of counselling. Our findings indicate that there is a role for education and practical training for improving sexual health care in the oncology practice.

**Compliance with Ethical Standards**

**Conflict of Interest** The author declares that they have no conflict of interest.
Appendix 1. Questionnaire medical oncologists (translated from Dutch)

*Demographics*

1. What is your gender? M/F

2. What is your age? ........ years

3. What is your function?
   - Oncologist
   - Haematologist
   - Oncologist-in-training (resident)
   - Haematologist-in-training (resident)

4. What is/are your area(s) of specialization?
   - Breast
   - Colorectal
   - Gynaecology
   - Hematology
   - Head and neck
   - Dermatology
   - Lung
   - Lymphoma
   - Nephro- and urology
   - Neuro-endocrine
   - Sarcoma
   - Palliative care
   - Other: ..............................................................

5. Where do you work?
   - Academic hospital
   - District general teaching hospital
   - District general hospital
   - Cancer institute
   - Academic and district general teaching hospital or district general hospital

6. How long do you practice as an oncologist?
   - < 1 year
   - 1-2 year
   - 3-5 year
   - 6-10 year
   - 11-15 year
   - > 15 year
If you never discuss sexual function, go to question 22.

6. If you discuss sexual function, with which patients would you do so? (multiple answers possible)
   Patients with:
   - Breast tumours
   - Colorectal tumours
   - Gynaecology tumours
   - Hematology tumours
   - Head and neck tumours
   - Skin tumours
   - Lung tumours
   - Lymphoma
   - Nephrologic tumours
   - Neuro-endocrine tumours
   - Urologic tumours
   - Sarcoma
   - Palliative care
   - Independent of tumour type
   - I don’t discuss sexual function
   - Other: .................................................................

7. With which type of treatment patients do you discuss sexual function? (multiple answers possible)
   - Treatment with intent to cure.
   - Life-prolonging treatment.
   - Palliative treatment.
   - Other: .................................................................

8. Could you please denote in the subsequent table how often you discuss sexual function with patients from the mentioned age categories?

| Age Category       | Never | Rarely | Regularly | Often |
|--------------------|-------|--------|-----------|-------|
| 16-35 year         | ☐     | ☐      | ☐         | ☐     |
| 36-50 year         | ☐     | ☐      | ☐         | ☐     |
| 51-65 year         | ☐     | ☐      | ☐         | ☐     |
| 66-75 year         | ☐     | ☐      | ☐         | ☐     |
| 76 year and older  | ☐     | ☐      | ☐         | ☐     |
9. Which percentage of your patients did you refer in the past year to a physician or other professional for support of sexual problems or for answering question concerning sexual function?

______% 

10. How often present patients sexual functioning complaints spontaneously?

☐ Never/ rarely
☐ In fewer than half of the cases
☐ In half of the cases
☐ In more than half of the cases
☐ Often/ always

11. How often do you make sure that sexual function is discussed with a new patient?

☐ Never/ rarely
☐ In fewer than half of the cases
☐ In half of the cases
☐ In more than half of the cases
☐ Often/ always

12. How much knowledge do you possess on sexual dysfunction resulting from cancer treatment?

☐ No knowledge at all
☐ Not so much knowledge
☐ Some knowledge
☐ Sufficient knowledge
☐ A lot of knowledge

13. In which way do you discuss the subject? (multiple answers possible)

☐ I don’t ask for it but I tell something about it.
☐ Patient raises the subject
☐ Addressing possible sexual side effects
☐ Closed questions
☐ Open questions
☐ Ask if the patient has questions about it
☐ Use a sense of humour
☐ I hardly or never discuss the subject.

14. If you discuss sexual functioning, what do you ask a female patient? (multiple answers possible)

☐ Fatigue
☐ Fear
☐ Not being able to enjoy
☐ Decreased libido

☐ Insufficient lubrication
☐ Dyspareunia
☐ Reaching an orgasm
15. What do you ask a male patient? (multiple answers possible)

- Fatigue
- Fear
- Not being able to enjoy
- Decreased libido
- Erectile dysfunction
- Reaching an orgasm
- Insecurity due to changed self-concept
- Insecurity due to changed appearance
- Sexual abuse
- Other:.............................

□ Insecurity due to changed self-concept
□ Menopause symptoms
□ Sexual abuse
□ Insecurity due to changed appearance
□ Other:.............................
16. Do you discuss sexual function during follow-up?

☐ Never/ rarely
☐ In fewer than half of the cases
☐ In half of the cases
☐ In more than half of the cases
☐ Often/ always

17. Do you ever describe phosphodiesterase inhibitor (Viagra or Cialis) to patients with erectile dysfunction?

☐ Never/ rarely
☐ In fewer than half of the cases
☐ In half of the cases
☐ In more than half of the cases
☐ Often/ always

19. Is in your department sufficient information on sexual function available to provide the patient with?

☐ Yes
☐ No
☐ I don’t know

20. If you discuss sexual function, do you ask for the sexual orientation of the patient? (Homosexual, lesbienne, bisexual?)

☐ Never/ rarely
☐ In fewer than half of the cases
☐ In half of the cases
☐ In more than half of the cases
☐ Often/ always

21. If you discuss sexual function, do you discuss concerns on ‘contagiousness’ of cancer during intercourse? (i.e. meaning the transmittance of cancer during intercourse; in case of for example testis-, penis- or cervix tumours)

☐ Never/ rarely
☐ In fewer than half of the cases
☐ In half of the cases
☐ In more than half of the cases
☐ Often/ always

22. Are problems on sexual function of the patients discussed during the multidisciplinary meetings?

☐ Yes
23. Is it from your department or from a protocol an obligation to discuss sexual function at any time?

- Yes
- No
- I don’t know

24. Is it from your department clear who is responsible to discuss sexual function with the patient? Is

- Yes
- No
- I don’t know

25. If you discuss sexual function, do you discuss the possible transmitting of chemotherapy agents to the partner during intercourse?

- Never/rarely
- In fewer than half of the cases
- In half of the cases
- In more than half of the cases
- Often/always

26. In the subsequent table are reasons that possibly keep you from discussing sexual function with your patients. To which extent do you agree with the statements? Please circle one square per statement.

| Reason                                                                 | Totally disagree | Disagree | Partly agree/partly disagree | Agree | Totally agree |
|------------------------------------------------------------------------|------------------|----------|-------------------------------|-------|---------------|
| Lack of time                                                           | □                | □        | □                             | □     | □             |
| Lack of knowledge                                                     | □                | □        | □                             | □     | □             |
| Lack of training                                                       | □                | □        | □                             | □     | □             |
| It is someone else’s task                                             | □                | □        | □                             | □     | □             |
| Patient is not ready to discussing sexual health                      | □                | □        | □                             | □     | □             |
| Surviving is more important                                           | □                | □        | □                             | □     | □             |
| Concerned about causing the patient discomfort                        | □                | □        | □                             | □     | □             |
| Reasons related to culture/religion                                   | □                | □        | □                             | □     | □             |
| Reasons related to language/ethnicity                                 | □                | □        | □                             | □     | □             |
| Age difference between you and                                        | □                | □        | □                             | □     | □             |
| patient                                      |   |   |   |   |   |
|---------------------------------------------|---|---|---|---|---|
| Afraid to offend the patient                |   |   |   |   |   |
| Sexuality is not a patient’s concern        |   |   |   |   |   |
| Not relevant for all type of cancers        |   |   |   |   |   |
| Patient is the opposite gender              |   |   |   |   |   |
| No angle or motive for asking               |   |   |   |   |   |
| Embarrassment                               |   |   |   |   |   |
| Advanced age of the patient                 |   |   |   |   |   |
| Sexuality is a private matter               |   |   |   |   |   |
| I feel uncomfortable                        |   |   |   |   |   |
| Patient is too ill                          |   |   |   |   |   |
| Patient is the same gender                  |   |   |   |   |   |
| Patient doesn’t bring up the subject        |   |   |   |   |   |
| No confidence in treatment for sexual dysfunction |   |   |   |   |   |
| Sexuality is not a matter of life or death  |   |   |   |   |   |
| Colleagues think it is inappropriate if I discus SF with patients |   |   |   |   |   |
| Presence of a third party                   |   |   |   |   |   |
27. The oncologist carries responsibility for discussing sexual function with patients.

- Totally agree
- Agree
- Disagree
- Totally disagree
- I don’t know

28. The oncology nurse carries responsibility for discussing sexual function with patients.

- Totally agree
- Agree
- Disagree
- Totally disagree
- I don’t know

29. Do you think it is important to screen for sexual concerns of cancer patients?

- Very important
- Important
- Rather important
- Slightly important
- Not important

30. With which patients do you believe sexual function should be discussed at least once? (multiple answers possible)

Patients with:

- Breast tumours
- Colorectal tumours
- Gynaecology tumours
- Hematology tumours
- Head and neck tumours
- Skin tumours
- Lung tumours
- Lymphoma
- Nephrologic tumours
- Neuro-endocrine tumours
- Urologic tumours
- Sarcoma
- Palliative care
- Independent of tumour type
- I believe discussing sexual function is not necessary.
- Other: .........................................................

31. Do you believe there is enough attention for sexual problems and counselling during the current oncology training?
27. The oncologist carries responsibility for discussing sexual function with patients.

☐ Totally agree
☐ Agree
☐ Disagree
☐ Totally disagree
☐ I don’t know

28. The oncology nurse carries responsibility for discussing sexual function with patients.

☐ Totally agree
☐ Agree
☐ Disagree
☐ Totally disagree
☐ I don’t know

29. Do you think it is important to screen for sexual concerns of cancer patients?

☐ Very important
☐ Important
☐ Rather important
☐ Slightly important
☐ Not important

30. With which patients do you believe sexual function should be discussed at least once? (multiple answers possible)

Patients with:

☐ Breast tumours
☐ Colorectal tumours
☐ Gynaecology tumours
☐ Hematology tumours
☐ Head and neck tumours
☐ Skin tumours
☐ Lung tumours
☐ Lymphoma
☐ Nephrologic tumours
☐ Neuro-endocrine tumours
☐ Urologic tumours
☐ Sarcoma
☐ Palliative care
☐ Independent of tumour type
☐ I believe discussing sexual function is not necessary.
☐ Other:..................................................
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Schover LR, van der Kaaij M, van Dorst E, Creutzberg C, Huyghe E, Kisend AC (2014) Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl 12(1):41–53
2. Kennedy V, Abramson E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST (2015) Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol 137(1):119–124
3. Martinez AMSJ, Ressle IB, Ayensu-Coker L, Thomas MA, Lindheim SR (2014) Sexual satisfaction is reduced in the female patient and sexually intimate partners following cancer therapy. Adv Sex Med 4:65–70
4. Incrocci L, Jensen PT (2013) Pelvic radiotherapy and sexual function in men and women. J Sex Med 10(Suppl 1):53–64
5. Ben Charif A, Bouhnik AD, Courbiere B, Rey D, Preau M, Bendiane MK et al (2016) Sexual health problems in French cancer survivors 2 years after diagnosis-the national VICAN survey. J Cancer Surviv 10(3):600–609
6. Bober SL, Varela VS (2012) Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 30(30):3712–3719
7. Scanlon M, Blaes A, Geller M, Majhail NS, Lindgren B, Haddad T (2012) Patient satisfaction with physician discussions of treatment impact on fertility, menopause and sexual health among pre-menopausal women with cancer. J Cancer 3:217–225
8. Condorelli M, Lambertini M, Del Mastro L, Boccardo F, Demeestere I, Bober SL (2019) Fertility, sexuality and cancer in young adult women. Curr Opin Oncol:1
9. Twitchell DK, Wittmann DA, Hotaling JM, Pastuszak AW (2019) Psychological impacts of male sexual dysfunction in pelvic cancer survivors. Sex Med Rev. Mar 26. https://doi.org/10.1016/j.smrx.2019.02.003
10. Flynn KE, Reese JB, Jeffery DD, Abernethy AP, Lin L, Shelby RA, Porter LS, Dombeck CB, Weinfurt KP (2012) Patient experiences with communication about sex during and after treatment for cancer. Psycho-oncology. 21(6):594–601
11. Wendt C (2017) Perception and assessment of verbal and written information on sex and relationships after hematopoietic stem cell transplantation. J Cancer Educ 32(4):681–689
12. Hordern AJ, Street AF (2007) Communicating about patient sexuality and intimacy after cancer: mismatched expectations and unmet needs. Med J Aust 186(5):224–227
13. Sporn NJ, Smith KB, Pirl WF, Lennes IT, Hyland KA, Park ER (2015) Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred? Psycho-oncology 24(9):1167–1173
14. Ben Charif A, Bouhnik AD, Courbiere B, Rey D, Preau M, Bendiane MK et al (2016) Patient discussion about sexual health with health care providers after cancer-a national survey. J Sex Med 13(11):1686–1694
15. Ussher JM, Perz J, Gilbert E, Wong WK, Mason C, Hobbs K et al (2013) Talking about sex after cancer: a discourse analytic study of health care professional accounts of sexual communication with patients. Psychol Health 28(12):1370–1390
16. Hordern AJ, Street AF (2007) Constructions of sexuality and intimacy after cancer: patient and health professional perspectives. Soc Sci Med 64(8):1704–1718
17. Crowley SA, Foley SM, Wittmann D, Jagielski CH, Dunn RL, Clark PM, Griggs JJ, Peterson C, Leonard M, An LC, Wei JT, Montie JE, Janz NK (2016) Sexual health concerns among cancer survivors: testing a novel information-need measure among breast and prostate cancer patients. J Cancer Educ 31(3):588–594
18. de Vocht H, Hordern A, Notter J, van de Wiel H (2011) Stepped skills: a team approach towards communication about sexuality and intimacy in cancer and palliative care. Australas Med J 4(11):610–619
19. Krouwel EM, Nicolai MP, van der Wielen GJ, Putter H, Pelger RC et al (2015) Sexual concerns after (pelvic) radiotherapy: is there any role for the radiation oncologist? J Sex Med 12(9):1927–1939
20. Krouwel EM, Hagen JH, Nicolai MP, Vahrmeijer AL, Putter H, Pelger RC et al (2015) Management of sexual side effects in the surgical oncology practice: a nationwide survey of Dutch surgical oncologists. Eur J Surg Oncol 41(9):1179–1187
21. Krouwel EM, Nicolai MP, van Steijn-van Tol AQ, Putter H, Osanto S, Pelger RC et al (2015) Addressing changed sexual functioning in

Questions on fertility assessment were located in this area but have been removed in this Appendix as they have not been used for this research proposal

Thank you very much for participating!
cancer patients: a cross-sectional survey among Dutch oncology nurses. Eur J Oncol Nurs 19(6):707–715
22. Hohwü L, Lyshol H, Gissler M, Jonsson SH, Petzold M, Obel C (2013) Web-based versus traditional paper questionnaires: a mixed-mode survey with a Nordic perspective. J Med Internet Res 15(8):e173
23. Zuidgeest M, Hendriks M, Koopman L, Spreeuwenberg P, Rademakers J (2011) A comparison of a postal survey and mixed-mode survey using a questionnaire on patients’ experiences with breast care. J Med Internet Res 13(3):e68
24. Kongsved SM, Basnov M, Holm-Christensen K, Hjollund NH (2007) Response rate and completeness of questionnaires: a randomized study of internet versus paper-and-pencil versions. J Med Internet Res 9(3):e25
25. Kwak N, Radler B A (2002) A comparison between mail and web surveys: response pattern, respondent profile, and data quality. J Off Stat 18(2):257–273
26. Hendriks AC, Vries dMC (2018) Recht op seksuele gezondheid en de rol van de arts. Ned Tijdschr Geneeskd 2018(162)
27. Storm C, Casillas J, Grunwald H, Howard DS, McNiff K, Neuss MM (2008) Informed consent for chemotherapy: ASCO member resources. J Oncol Pract 4(6):289–295
28. Nicolosi A, Buvat J, Glasser DB, Hartmann U, Laumann EO, Gingell C (2006) Sexual behaviour, sexual dysfunctions and related help seeking patterns in middle-aged and elderly Europeans: the global study of sexual attitudes and behaviors. World J Urol 24(4):423–428
29. Wang K, Ariello K, Choi M, Turner A, Wan BA, Yee C, Rowbottom L, Macdonald R, Lam H, Drost L, Chow E (2018) Sexual healthcare for cancer patients receiving palliative care: a narrative review. Ann Palliat Med 7(2):256–264
30. Wang LY, Pierdemonico A, Lefkowitz A, Brandt R (2015) Female sexual health training for oncology providers: new applications. Sex Med 3(3):189–197
31. Jonsdottir JI, Zoega S, Saevardsdottir T, Sverrisdottir A, Thordsdottir T, Einarsson GV et al (2016) Changes in attitudes, practices and barriers among oncology health care professionals regarding sexual health care: outcomes from a 2-year educational intervention at a university hospital. Eur J Oncol Nurs 21:24–30
32. Hartmann U, Burkart M (2007) Erectile dysfunctions in patient-physician communication: optimized strategies for addressing sexual issues and the benefit of using a patient questionnaire. J Sex Med 4(1):38–46

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.